Shares of Verastem (VSTM) have been struggling lately and have lost 16.4% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the s ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 8194537 at. ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Oct. 21:Verastem, Inc. (VSTM) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 21.5% over the last 60 days.Verastem’s shares gained 52.2% over the last three months compared with the S&P 500’s advance of 5.7%. The company possesses a Momentum Score  of A.Amer Sports, Inc. (AS) : This sports and outdoor brands company ...

Core Insights - Five stocks have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment returns Group 1: Company Earnings Estimates - Newmont Corporation (NEM) has seen a 6.9% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Royal Bank of Canada (RY) has experienced a 5.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Amer Sports, Inc. (AS) has seen a 9.1% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Verastem, Inc. (VSTM) has experienced a significant 21.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Sono-Tek Corporation (SOTK) has seen a remarkable 37.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Core Insights - Verastem Oncology is collaborating with GenFleet Therapeutics to develop GFH375 (VS-7375) for advanced KRAS G12D mutant pancreatic ductal adenocarcinoma, aiming to provide new treatment options for patients with limited choices [1][6] - RBC Capital maintains an "Outperform" rating on Verastem's stock, currently trading at $8.32, with a price target of $13, indicating a potential increase of 62.3% [2][5] - Despite a negative price-to-earnings (P/E) ratio of -3.38 and an enterprise value to operating cash flow ratio of -3.62, the company's strong current ratio of 3.46 suggests a solid ability to meet short-term liabilities [2][3][4] Financial Metrics - The debt-to-equity ratio of Verastem stands at 2.09, indicating a higher level of debt compared to equity [4] - The ongoing study with GenFleet Therapeutics could significantly enhance Verastem's market position and financial outlook if successful [4][5] - RBC Capital's positive outlook reflects confidence in Verastem's strategic initiatives and potential breakthroughs in oncology [5][6]

Core Insights - Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer patients, attracting attention from momentum investors due to its recent performance and analyst projections [1] Price Targets and Performance - RBC Capital set a price target of $13 for Verastem, indicating a potential increase of 62.3% from the current stock price of $8.01 [2][6] - Zacks Investment Research assigned Verastem a Momentum Style Score of A, suggesting strong potential for continued positive performance, with a current trading price of $9.22 and a 1.9% gain over the past four weeks [3][6] - Wall Street analysts have a price target range for Verastem from $13 to $20, indicating potential increases of 41% to 116.9% [5][6] Stock Performance and Market Data - The stock price has recently decreased by 7.97% to $8.49, with a trading range today between $6.98 and $9.02, and a yearly range from a low of $2.95 to a high of $11.25 [4] - Verastem's market capitalization is approximately $522.2 million, with a trading volume of 4,762,954 shares on the NASDAQ exchange [4]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

Verastem (VSTM) closed the last trading session at $9.22, gaining 1.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.5 indicates a 68.1% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $2.62. While the lowest estimate of $13.00 indicates a 41% increase from the current price level, the most optimistic analyst expects th ...

Core Insights - Verastem Oncology announced positive updated efficacy and safety data from GenFleet Therapeutics' Phase 1/2 monotherapy study of GFH375, an oral KRAS G12D inhibitor for advanced pancreatic ductal adenocarcinoma [1] Company Summary - Verastem Oncology is focused on developing new medicines for patients with RAS/MAPK-pathway-driven cancers [1] - GFH375, also known as VS-7375 outside of China, targets KRAS G12D mutations in advanced pancreatic ductal adenocarcinoma [1] Study Details - The study involved 59 heavily pre-treated patients, indicating a significant patient population for evaluating the drug's efficacy and safety [1]

Core Insights - The investment thesis for Verastem (NASDAQ: VSTM) appears optimistic based on previous analyses and recent developments in the biotech sector [1] Company Analysis - Verastem is focused on the science behind its business, emphasizing the importance of understanding clinical trials and the underlying biochemistry [1] Industry Context - The article highlights the significance of due diligence in biotech investments, suggesting that investors should be well-informed to avoid potential pitfalls in this volatile sector [1]